SUNY Upstate Medical University, Syracuse, NY, 13210, USA.
Curr Cardiol Rep. 2014 Mar;16(3):463. doi: 10.1007/s11886-013-0463-2.
Anticoagulation remains the cornerstone of treatment in patients with deep vein thrombosis (DVT). While parenteral anticoagulants and oral vitamin K antagonists (e.g., warfarin) have been used for many decades, the recent development of novel oral anticoagulants have provided clinicians with an expanding set of therapeutic options for DVT. This review summarizes the pharmacology and clinical trial results of these new oral anticoagulants. Several practical considerations to the use of these oral anticoagulants including issues related to adherence, monitoring, and reversal are also discussed.
抗凝治疗仍然是深静脉血栓形成（DVT）患者的基石。虽然几十年来一直使用肠外抗凝剂和口服维生素 K 拮抗剂（如华法林），但新型口服抗凝剂的最近发展为临床医生提供了一系列用于 DVT 的治疗选择。本综述总结了这些新型口服抗凝剂的药理学和临床试验结果。还讨论了使用这些口服抗凝剂的一些实际考虑因素，包括与依从性、监测和逆转相关的问题。
